CXCL8, CCL2, and CMV Seropositivity as New Prognostic Factors for a Severe COVID-19 Course
Ewa Pius‐Sadowska, Anna Niedźwiedź, Piotr Kulig, Bartłomiej Baumert, Anna Sobuś, Dorota Rogińska, Karolina Łuczkowska, Zofia Ulańczyk, Szymon Wnęk, Igor Karolak, Edyta Paczkowska, Katarzyna Kotfis, Miłosz Kawa, Iwona Stecewicz, Piotr Zawodny, Bogusław Machaliński
Abstract
The exact pathophysiology of severe COVID-19 is not entirely elucidated, but it has been established that hyperinflammatory responses and cytokine storms play important roles. The aim of this study was to examine CMV status, select chemokines, and complement components in COVID-19, and how concentrations of given molecules differ over time at both molecular and proteomic levels. A total of 210 COVID-19 patients (50 ICU and 160 non-ICU patients) and 80 healthy controls were enrolled in this study. Concentrations of select chemokines (CXCL8, CXCL10, CCL2, CCL3, CCR1) and complement factors (C2, C9, CFD, C4BPA, C5AR1, CR1) were examined at mRNA and protein levels with regard to a COVID-19 course (ICU vs. non-ICU group) and CMV status at different time intervals. We detected several significant differences in chemokines and complement profiles between ICU and non-ICU groups. Pro-inflammatory chemokines and the complement system appeared to greatly contribute to the pathogenesis and development of severe COVID-19. Higher concentrations of CXCL8 and CCL2 in the plasma, with reduced mRNA expression presumably through negative feedback mechanisms, as well as CMV-positive status, correlated with more severe courses of COVID-19. Therefore, CXCL8, CCL2, and CMV seropositivity should be considered as new prognostic factors for severe COVID-19 courses. However, more in-depth research is needed.